Transgene Biotek Ltd faces a sudden governance development after its statutory auditor, M/s. Harish Gummadi & Co., resigned one day following their appointment. The firm cited an unforeseen family medical emergency as the primary reason. As no audit reviews were conducted, the company must now quickly appoint a successor to meet regulatory compliance requirements for the September quarter results.
Transgene Biotek Auditor Resigns After Single Day Tenure
Resignation effective date: November 3, 2026. Auditor tenure: One day.
Reader Takeaway: Immediate auditor resignation creates governance uncertainty; shareholders should await the appointment of a replacement auditor.
What just happened
Transgene Biotek Ltd has officially notified the stock exchange regarding the resignation of M/s. Harish Gummadi & Co. from its role as statutory auditor. The resignation became effective on November 3, 2026, just one day after the firm was originally appointed to the position on November 2, 2026.
Why this matters
Auditor resignations, especially those occurring almost immediately after appointment, frequently draw scrutiny from the investor community regarding corporate governance standards. While the outgoing auditor has explicitly stated that the decision was driven by an "unforeseen medical emergency in the immediate family," such abrupt departures often prompt questions about audit oversight and potential delays in financial reporting.
The current status
The outgoing auditor confirmed that no audit or limited review reports were completed or issued during their single-day tenure. Crucially, the auditor noted an inability to allocate the necessary time and resources to conduct the limited review for the quarter ended September 30, 2026. This review is a regulatory requirement that must be completed by November 14, 2026.
What changes now
Transgene Biotek has publicly committed to initiating the process for appointing a new statutory auditor in accordance with the Companies Act, 2013, and SEBI (Listing Obligations and Disclosure Requirements) Regulations. The company must expedite this search to ensure the September quarter results are reviewed within the statutory deadline.
What to track next
Investors should closely monitor future BSE filings for the announcement of a new audit firm. Any significant delay in filing the quarterly financial results could act as a negative signal for the stock.